Cognitive Improvement Effects of Polymer-Based Microencapsulated Celecoxib in a Rat Model of Alzheimer’s Disease

Objective: The microencapsulation of Celecoxib (CXB) using different polymers aimed to enhance its solubility and permeability profile for potential neuroprotective applications in neurodegenerative diseases like Alzheimer’s disease. Methods: The solvent evaporation method was used for microencapsulation of CXB formulation. Characterization and evaluation of microencapsulation was done by FT-IR, DSC, XRD, SEM, and dissolution methods. Neuroprotective effect was evaluated by Scopolamine induced rat model. Results and Discussion: The solvent evaporation method yielded microencapsulated CXB formulations with high drug loading and improved dissolution profiles. Scanning electron microscopy revealed morphological changes, while differential scanning calorimetry and X-ray diffraction confirmed the conversion of CXB to an amorphous state post-encapsulation. Fourier-transform infrared spectroscopy indicated the formation of hydrogen bonds between CXB and polymers. In behavioral studies, microencapsulated CXB demonstrated superior efficacy in mitigating cognitive impairment induced by scopolamine, suggesting its potential as a neuroprotective agent. This effect may be attributed to the activation of cholinergic pathways. Conclusions: Thus, microencapsulation presents a promising strategy to enhance the therapeutic efficacy of CXB for neurodegenerative disorders.